Design Therapeutics Q3 net loss $13.0M; FECD Phase 1 trial initiated, data H1 2025

Design Therapeutics, Inc.

2024-Q3 EPS reported -$0.64

Net loss of $13.0M for Q3 2024; R&D expense $11.9M, G&A expense $4.4M.
Cash and securities $254.1M as of Sep 30, 2024; expected to fund operations into 2029.
FECD DT-168 Phase 1 trial initiated in healthy volunteers; initial data expected H1 2025.
FA DT-216P2 Phase 1 single ascending dose study in healthy volunteers on track for H1 2025.
Preclinical programs advancing toward development candidate selection in HD and DM1.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.